Srinivas Nalamachu
University of Kansas
Physical therapyOpioidChronic painAnesthesiaMedicine
What is this?
Publications 76
The Chronic pain epidemic is a pressing public health crises facing the United States. Currently, more than 100 million Americans suffer from chronic pain, with chronic pain being among the most prevalent conditions and the leading cause of disability. Chronic pain disproportionately affects certain populations including women, low-income individuals, and older adults. This article focuses primarily on new molecular entities in development targeting various chronic pain receptors and new deliver...
#1Srinivas NalamachuH-Index: 18
Last. Robert B. RaffaH-Index: 44
view all 5 authors...
Opioids are a treatment option for a variety of chronic pain conditions. But long-term opioid use can be associated with side effects, including hypogonadism. Opioid-induced hypogonadism (OIhG) is associated with the alteration of the hypothalamic-pituitary-gonadal axis (HPG). In males, hypogonadism can result in erectile dysfunction, reduced libido, fatigue, worsening mood, and increased risk of osteoporosis; in females, it can result in changes in the menstrual cycle and reduced libido, among ...
Deaths from opioid overdoses have increased dramatically over the past few years. Given that immediate-release (IR) opioids account for most of the U.S. market share, and that abusers generally prefer IR opioids over extended-release (ER) opioids, it is not surprising that rates of abuse are higher for IR than ER opioids. IR opioids are widely prescribed, often without consideration for risks of abuse, misuse, and diversion. Prescription opioid abuse and misuse often begins through oral administ...
3 CitationsSource
#1Srinivas NalamachuH-Index: 18
#2Jeffrey A. Gudin (Englewood Hospital and Medical Center)H-Index: 9
Last. Yiqun Hu (AstraZeneca)H-Index: 1
view all 6 authors...
Objective: Efficacy and safety of naloxegol, a peripherally acting μ-opioid receptor antagonist that significantly reduces opioid-induced constipation (OIC), were assessed for patient subgroups defined post hoc by baseline maintenance opioid characteristics. Design: Post hoc, pooled analysis of data from two 12-week, randomized, double-blind, placebo-controlled, phase 3 studies. Setting: Two hundred fifty-seven outpatient centers in the United States and Europe. Patients: Patients with noncancer...
1 CitationsSource
#1Richard RauckH-Index: 39
#2D. Alexander OhH-Index: 3
Last. Steven JamesH-Index: 1
view all 8 authors...
Background and Objectives Fentanyl sublingual spray may be a viable alternative to intravenous (IV) opioids for the treatment of acute pain. As patients with acute pain may include those who have limited prior exposure to opioids, this phase 1, open-label, randomized, multiple ascending-dose study was conducted to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of multiple doses of fentanyl sublingual spray in opioid-naive participants. This article primarily reports the ...
2 CitationsSource
#1Lynn R. WebsterH-Index: 34
#2Srinivas NalamachuH-Index: 18
view all 7 authors...
AbstractThe long-term safety of naldemedine, a peripherally acting µ-opioid receptor antagonist, was evaluated in patients with opioid-induced constipation and chronic noncancer pain in a 52-week, randomized, double-blind, phase 3 study. Eligible adults who could be on a routine laxative regimen wer
19 CitationsSource
AbstractObjective: Fentanyl sublingual spray offers rapid pain relief in opioid-tolerant cancer patients, and may be useful in acute or post-operative pain. Both opioid-naive and non-tolerant patients are likely to receive opioids in these settings. Understanding the relationship between systemic exposure of fentanyl sublingual spray and effects on respiratory function in opioid-naive or non-tolerant populations is important to ensure patient safety. This study evaluated single-dose fentanyl sub...
3 CitationsSource
#1Richard RauckH-Index: 39
#2John D. MarkmanH-Index: 20
Last. Nathaniel P. KatzH-Index: 53
view all 10 authors...
#1Robert B. Raffa (TU: Temple University)H-Index: 44
#2Robert TaylorH-Index: 17
Last. Evan T. EdwardsH-Index: 4
view all 6 authors...
The increased use of opioids for chronic treatment of pain and the resulting epidemic of opioid overdoses have created a major public health challenge. Parenteral naloxone has been used since the 1970’s to treat opioid overdose. Recently, a novel naloxone auto-injector device (EVZIO, kaleo, Inc., Richmond, VA) was approved by the Food and Drug Administration. In this article, we review the Human Factors Engineering (HFE) process used in the development and testing of this novel naloxone auto-inj...
7 CitationsSource